Ignite Creation Date:
2025-12-25 @ 3:30 AM
Ignite Modification Date:
2026-05-18 @ 2:12 AM
Study NCT ID:
NCT05104905
Status:
WITHDRAWN
Last Update Posted:
2022-05-11
First Post:
2021-10-22
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma
Sponsor:
Faron Pharmaceuticals Ltd
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
FP2CLI003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None